The company that filed nearly a dozen lawsuits alleging drug makers devised schemes in which nurses were used illegally to promote medicines and boost prescriptions has filed blistering responses to a federal government effort to dismiss the cases.
In court filings, the National Health Care Analysis Group took the U.S. Department of Justice to task for misunderstanding the issues raised in its whistleblower lawsuits, maintained the government never fully investigated the allegations, and suggested a conflict of interest in the Executive Branch may have influenced the decision to have the cases tossed.
The company claimed the Justice Department “lacked a basic understanding of the allegations … and whether the government likes it or not, this is a meritorious action. And before it may dismiss it, the government was required to make at least some showing, evidentiary or otherwise, that amounts to more than boilerplate and unsupported attorney say-so.”
About the Author Reprints
